DE60043070D1 - Proteine-abgabe durch polare epithelzellen schichte - Google Patents

Proteine-abgabe durch polare epithelzellen schichte

Info

Publication number
DE60043070D1
DE60043070D1 DE60043070T DE60043070T DE60043070D1 DE 60043070 D1 DE60043070 D1 DE 60043070D1 DE 60043070 T DE60043070 T DE 60043070T DE 60043070 T DE60043070 T DE 60043070T DE 60043070 D1 DE60043070 D1 DE 60043070D1
Authority
DE
Germany
Prior art keywords
bioactive
epithelial cells
protein delivery
moiety
polar epithelial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60043070T
Other languages
English (en)
Inventor
David J Fitzgerald
Randall J Mrsny
Miriam Mckee
Ann Daugherty
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Genentech Inc
Original Assignee
US Department of Health and Human Services
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services, Genentech Inc filed Critical US Department of Health and Human Services
Application granted granted Critical
Publication of DE60043070D1 publication Critical patent/DE60043070D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE60043070T 1999-10-22 2000-10-18 Proteine-abgabe durch polare epithelzellen schichte Expired - Lifetime DE60043070D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16092399P 1999-10-22 1999-10-22
PCT/US2000/029080 WO2001030392A2 (en) 1999-10-22 2000-10-18 Delivery of proteins across polar epithelial cell layers

Publications (1)

Publication Number Publication Date
DE60043070D1 true DE60043070D1 (de) 2009-11-12

Family

ID=22579051

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60043070T Expired - Lifetime DE60043070D1 (de) 1999-10-22 2000-10-18 Proteine-abgabe durch polare epithelzellen schichte

Country Status (8)

Country Link
US (1) US7824695B1 (de)
EP (1) EP1242122B1 (de)
JP (2) JP2003512441A (de)
AT (1) ATE444081T1 (de)
AU (1) AU784657B2 (de)
CA (1) CA2389302C (de)
DE (1) DE60043070D1 (de)
WO (1) WO2001030392A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2295971C (en) * 1997-07-11 2011-02-08 THE GOVERNMENT OF THE UNITED STATES, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Pseudomonas exotoxin a-like chimeric immunogens
AU784657B2 (en) * 1999-10-22 2006-05-18 Genentech Inc. Delivery of proteins across polar epithelial cell layers
JP2008515808A (ja) * 2004-10-04 2008-05-15 トリニティ バイオシステムズ インコーポレーテッド 針不用の高分子送達のための方法及び組成物
WO2007067596A2 (en) * 2005-12-05 2007-06-14 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of antibodies
EP1971367A4 (de) * 2005-12-05 2010-04-07 Trinity Biosystems Inc Verfahren und zusammensetzungen zur nadellosen abgabe von bindungspartnern
EP2010205A2 (de) * 2006-03-16 2009-01-07 Trinity Biosystems, Inc. Verfahren zur erhöhung der grösse von tieren mit nadellos abgegebenen konstrukten
US11246915B2 (en) 2010-09-15 2022-02-15 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
EP4316586A3 (de) 2018-03-08 2024-05-08 Applied Molecular Transport Inc. Toxinabgeleitete freisetzungskonstrukte zur oralen freisetzung
BR112021009001A8 (pt) 2018-11-07 2021-10-26 Applied Molecular Transport Inc Veículos derivados de cholix para administração oral de carga útil heteróloga
CA3150859A1 (en) 2019-08-16 2021-02-25 Applied Molecular Transport Inc. Compositions, formulations, and interleukin production and purification

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL78775A (en) * 1985-05-15 1992-06-21 Biotech Australia Pty Ltd Oral vaccines
WO1994000481A1 (en) * 1992-06-23 1994-01-06 Associated Synapse Biologics Pharmaceutical composition containing botulinum b complex
EP0717753B1 (de) * 1993-09-06 1998-12-02 Menarini Ricerche S.p.A. Ribosom-inaktievirende proteine, die aus saponaria ocymoides und vaccaria pyramidata samen extrahiert sind sowie deren herstellung und immunotoxine, die sie enthalten
DE69522216T2 (de) 1994-05-13 2002-05-02 Biovation Ltd Zielzellen-bindende chimäre Peptide
DE69729389D1 (de) * 1996-11-06 2004-07-08 Nasa Protease-aktivierbare pseudomonas exotoxin-a-ähnliche proproteine
WO1998042876A1 (en) * 1997-03-26 1998-10-01 Board Of Regents, The University Of Texas System Methods and compositions for using membrane-penetrating proteins to carry materials across cell membranes
CA2295971C (en) * 1997-07-11 2011-02-08 THE GOVERNMENT OF THE UNITED STATES, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Pseudomonas exotoxin a-like chimeric immunogens
US20030054012A1 (en) 2000-05-12 2003-03-20 Fitzgerald David J. Pseudomonas exotoxin a-like chimeric immunogens for eliciting a secretory iga-mediated immune response
US6472140B1 (en) * 1997-09-05 2002-10-29 The General Hospital Corporation α-2- macroglobulin therapies and drug screening methods for Alzheimer's disease.
AU784657B2 (en) * 1999-10-22 2006-05-18 Genentech Inc. Delivery of proteins across polar epithelial cell layers
ATE331788T1 (de) * 1999-10-22 2006-07-15 Us Gov Health & Human Serv Disulfidkonjugierte zellgifte und verfahren zur ihrer herstellung und verwendung
WO2002060935A2 (en) 2000-12-21 2002-08-08 The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services A chimeric protein comprising non-toxic pseudomonas exotoxin a and type iv pilin sequences

Also Published As

Publication number Publication date
JP2003512441A (ja) 2003-04-02
WO2001030392A3 (en) 2002-07-11
US7824695B1 (en) 2010-11-02
JP2012051939A (ja) 2012-03-15
AU784657B2 (en) 2006-05-18
WO2001030392A2 (en) 2001-05-03
EP1242122B1 (de) 2009-09-30
CA2389302A1 (en) 2001-05-03
EP1242122A2 (de) 2002-09-25
CA2389302C (en) 2011-03-15
ATE444081T1 (de) 2009-10-15
AU1339201A (en) 2001-05-08

Similar Documents

Publication Publication Date Title
Niedel et al. Receptor-mediated internalization of fluorescent chemotactic peptide by human neutrophils
NO2017027I2 (no) efmoroctocog alfa eller et biotilsvarende legemiddel ihht Artikkel 10(4) av Directive 2001/83/EC, som beskyttet av basispatentet.
ATE517922T1 (de) Stabilisierte einzel-domänen-antikörper in einer pharmazeutischen zusammensetzung ausgestaltet für inhalation
CY1118504T1 (el) Τριμερης πρωτεϊνη συντηξης του συνδετη οχ40 στην περιοχη ανοσοσφαιρινης και τροποι χρησης
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
NO20063026L (no) Antistoffer
IL152886A0 (en) B-7 related nucleic acids and polypeptides and pharmaceutical compositions containing the same
PT835266E (pt) Superantigenios modificados / quimericos e seu uso
DE69633617D1 (de) Il-17 receptor
ATE127153T1 (de) Zellen mit ausgestattener antikörperspezifität.
DE60025832D1 (de) Mehrere zytokin-antikörper komplexen
DE60043070D1 (de) Proteine-abgabe durch polare epithelzellen schichte
DK1347730T4 (da) Rekombinante anti-CD30-antistoffer og anvendelser deraf
OA07388A (fr) Nouveaux conjugués associant, par liaison convalente, une enzyme et un anticorps et associations médicamenteuses utilisant lesdits conjugués.
BRPI0515615A (pt) métodos para tratar células cancerosas e doença imune relacionada
ATE223229T1 (de) Zusammensetzungen aus konjugaten des stabilen, aktiven, menschlichen ob proteins mit der fc kette von immunoglobulinen und damit zusammenhängende verfahren
ES2187946T3 (es) Uso de interleucina-15.
ATE328611T1 (de) Multiple,kohlenhydrathaltige glycopeptid-antigene,daraus entwickelte impfstoffe sowie deren verwendung
DE69726674D1 (de) Zellmodulierende konjugate aus elementen aus spezifischen bindungspaaren
ATE297219T1 (de) Antikörper als arzneimittel gegen lymphocytische tumore (ausschliesslich myelome)
ATE311464T1 (de) Nk zellen-aktivierende rezeptoren und deren therapeutische und diagnostische verwendungen
DK1331944T3 (da) Anvendelse af CD28-specifikke monoklonale antistoffer til stimulering af blodlegemer, der ikke bærer CD28
Pelletier et al. Down modulation of Heymann's nephritis by mercuric chloride
WO2001059073A3 (en) Cytotoxic t lymphocytes activated by dendritic cell hybrids
AR010333A1 (es) Una muteina ob, una secuencia de adn, un vector de expresion una celula hospedadora procariota o de mamifero, un baculovirus recombinante, una celulahospedadora, un metodo para la produccion de una muteina ob, una composicion farmaceutica, el uso de una proteina ob para la preparacion de una composi

Legal Events

Date Code Title Description
8364 No opposition during term of opposition